Drug combination for EGFR-positive advanced pancreatic cancer after prior treatment
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug combination (becotatug vedotin, an immunotherapy called anti-PD-1, and a chemotherapy pill called S-1) for people with advanced pancreatic cancer that has EGFR protein and has already been treated with at least one standard therapy. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with pancreatic cancer that has spread or cannot be fully removed by surgery.
- You have already had at least one round of standard chemotherapy or other drug treatment for your cancer.
- Your tumor tests positive for EGFR protein (a marker on cancer cells) – your doctor can confirm this from a biopsy or previous test.
- You are generally able to take care of yourself (ECOG performance status 0 to 3, meaning you can be up and about, though you may need some help).
- You have at least one tumor that can be measured on a scan, and your blood counts and organ function (liver, kidneys, thyroid) are within acceptable levels.
- You are not pregnant and agree to use effective birth control during treatment and for 120 days after if there is any risk of pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs and radiation for people with pancreatic cancer that has spread. It aims to shrink tumors and improve quality of life by using an immunotherapy drug, two chemotherapies, and precisely targeted radiation.
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
This trial tests a new combination of drugs (including an investigational immunotherapy and a targeted pill, plus standard chemotherapy) as the first treatment for pancreatic cancer that cannot be removed with surgery. It may help shrink tumors or slow the cancer's growth.
This study tests a combination of drugs (an investigational immunotherapy, a targeted therapy, and chemotherapy) as a second-line treatment for people with advanced pancreatic cancer. The goal is to see if this combination can help slow down or stop the cancer when the first treatment no longer works.
This trial tests a new targeted drug (LM-302) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that has progressed after initial treatment. The goal is to see if this combination can slow down or shrink the cancer.
This study tests a new combination of two drugs for advanced pancreatic cancer. It aims to see if adding an immunotherapy drug (which helps your immune system attack cancer) to standard chemotherapy can help control the cancer better.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.